Department of Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Breast Cancer Res Treat. 2021 Oct;189(3):759-768. doi: 10.1007/s10549-021-06322-4. Epub 2021 Jul 20.
Body composition, including sarcopenia and fat parameters, has received much attention as a prognostic factor in breast cancer.
A total of 479 breast cancer patients who underwent surgery and received adjuvant chemotherapy were enrolled in this study. Body composition, including the index and density of skeletal muscle, visceral fat, subcutaneous fat, and intermuscular fat calculated by CT scan, was used as a prognostic factor. The endpoints were breast cancer-specific survival (BCSS) and overall survival (OS).
The number of patients with stages I, II, and III was 146 (30.5%), 237 (49.5%), and 96 (20%), respectively. Sarcopenia and muscle density were not significant prognostic factors for BCSS and OS. A high visceral fat index (VFI) was an independent prognostic factor for BCSS (HR, 2.55; 95% CI 1.10-5.95, p = 0.03) and OS (HR 2.55, 95% CI 1.26-5.16, p = 0.01). In addition, high intermuscular fat density (IMFD) was also a significant prognostic factor for BCSS (HR, 2.95; 95% CI 1.34-6.46, p = 0.007) and OS (HR 2.28, 95% CI 1.22-4.26, p = 0.01) in multivariate analysis.
VFI and IMFD were significant prognostic factors for BCSS and OS in breast cancer patients treated with adjuvant chemotherapy.
体成分，包括肌少症和脂肪参数，作为乳腺癌的预后因素受到了广泛关注。
本研究共纳入 479 例接受手术和辅助化疗的乳腺癌患者。使用 CT 扫描计算的骨骼肌指数和密度、内脏脂肪、皮下脂肪和肌间脂肪等体成分作为预后因素。终点为乳腺癌特异性生存（BCSS）和总生存（OS）。
Ⅰ期、Ⅱ期和Ⅲ期患者分别为 146 例（30.5%）、237 例（49.5%）和 96 例（20%）。肌少症和肌肉密度不是 BCSS 和 OS 的显著预后因素。高内脏脂肪指数（VFI）是 BCSS（HR，2.55；95%CI 1.10-5.95，p=0.03）和 OS（HR 2.55，95%CI 1.26-5.16，p=0.01）的独立预后因素。此外，高肌间脂肪密度（IMFD）也是 BCSS（HR，2.95；95%CI 1.34-6.46，p=0.007）和 OS（HR 2.28，95%CI 1.22-4.26，p=0.01）的显著预后因素。
在接受辅助化疗的乳腺癌患者中，VFI 和 IMFD 是 BCSS 和 OS 的显著预后因素。
